Polyendocrine Metabolic
Ovarian Syndrome
Prior attempts to rename PCOS stalled due to lack of inclusive global leadership, absence of coordinated international consensus, misalignment between patient advocacy groups, no agreed alternative, and no implementation strategy. This 2026 process was the first to address all five barriers simultaneously — securing dedicated funding, governance across 56 organizations, iterative Delphi methods, nominal group technique workshops across world regions, and a co-designed implementation roadmap.
The old name "polycystic ovary syndrome" was misleading. The word "polycystic" makes it sound like you have cysts on your ovaries — but most women with this condition do not have harmful cysts. The old name made it seem like only the ovaries were affected, when in fact this condition affects the whole body — including hormones, metabolism, heart health, and mental wellbeing.
The new name — PMOS — is more accurate. It describes a condition involving many hormones (polyendocrine), the way your body processes energy (metabolic), and how your ovaries work (ovarian).
No. If you were diagnosed with PCOS, you now have PMOS. Same condition, better name. Your treatment plan, medications, and care do not change because of the renaming. Talk to your doctor if you have questions about what this means for you specifically.
This wasn't a decision made by a small group of doctors. It was a worldwide effort that started years ago and involved over 14,000 people — including women living with the condition and doctors from dozens of countries.
People answered surveys about what the name should communicate, what stigma they wanted to avoid, and what would be most helpful. They held workshops across the world. They consulted branding experts. They tested dozens of possible names. The goal was a name that was scientifically accurate, easy to understand, and didn't cause additional shame or confusion.
Poly-endocrine: "Many hormones." This condition involves several hormones that are out of balance — not just one.
Metabolic: Affects how your body processes energy, blood sugar, and fat. Insulin resistance is central.
Ovarian: The ovaries are still involved — but the word "cysts" has been removed because most people don't actually have harmful cysts.
Irregular or absent menstrual cycles reflecting disordered ovulation. In clinical practice: cycles <21 days or >35 days, or fewer than 8 cycles per year. In adolescents, irregular cycles are normative in the first 2 years post-menarche — caution required.
Clinical: Hirsutism (modified Ferriman-Gallwey score), acne, androgenic alopecia.
Biochemical: Elevated calculated free testosterone or total testosterone (mass spectrometry preferred). DHEAS and androstenedione may supplement. Note ethnic variation in hirsutism cut-offs (Bizuneh et al., 2025).
Ultrasound: ≥20 follicles per ovary (2–9mm) on transvaginal US (updated threshold from 2023 guidelines), or ovarian volume >10 mL in at least one ovary, excluding dominant follicle/cyst.
AMH: Now included in adult diagnostic criteria per 2023 guidelines. Threshold varies by assay and age. (van der Ham et al., Fertil Steril 2024)
Before diagnosis, exclude: thyroid dysfunction (TSH), hyperprolactinemia (prolactin), congenital adrenal hyperplasia (17-OHP), Cushing syndrome, androgen-secreting neoplasm. Consider premature ovarian insufficiency if relevant.
In adolescents (age 10–19 years), both criteria 1 and 2 must be present. Polycystic ovarian morphology alone is not sufficient for diagnosis in this age group, as multi-follicular ovaries are common in adolescence and AMH data in this population is less definitive. The 2023 International Guidelines provide specific thresholds for adolescent assessment. (Peña et al., BMC Med 2025)
Multiple studies have confirmed that pathological ovarian cysts are not increased in PMOS compared to controls. (Piltonen et al., JAMA Intern Med 2026; Pea et al., Hum Reprod Update 2024). The classic ultrasonographic appearance reflects arrested follicular development (small antral follicles, 2–9mm), not true cysts. This distinction is clinically important in patient counseling and has been a primary driver of the name change.
Periods that come less than every 21 days, more than every 35 days, or fewer than 8 times a year. This happens because the ovaries aren't releasing eggs regularly.
Androgens are often called "male hormones," but women produce them too — just in smaller amounts. With PMOS, these levels are higher than normal. This can cause: extra hair growth on the face, chest, or back; acne; or hair thinning on the scalp. Your doctor can also measure this with a blood test.
An ultrasound may show many small follicles in your ovaries. Note: these are not dangerous cysts — they are small fluid-filled sacs that are part of the normal process but aren't developing fully. Alternatively, a blood test called AMH (anti-Müllerian hormone) can show elevated levels.
- Ovulatory dysfunction
- Irregular menstrual cycles
- Subfertility / infertility
- Pregnancy complications (preeclampsia, GDM, preterm birth)
- Endometrial cancer (unopposed estrogen from anovulation)
- Elevated AMH (disordered folliculogenesis)
- Depression
- Anxiety
- Eating disorders
- Reduced quality of life
- Distress linked to condition name itself
- Stigma, particularly in fertility-focused cultures
- Hirsutism (androgen-driven terminal hair growth)
- Acne (often adult-onset)
- Androgenic alopecia
- Ethnic variation in hirsutism expression
Source: Tay et al., J Am Heart Assoc 2024 — predominantly premenopausal women. Odds ratios vs. controls without PMOS.
PMOS involves several hormones that are out of balance at the same time. Your brain sends too many signals to your ovaries, causing them to produce too many androgens ("male-type" hormones). Your body also has trouble using insulin properly (called insulin resistance), which makes the hormone imbalance worse.
Insulin is the hormone that helps your body use sugar for energy. In PMOS, your cells don't respond to insulin as well as they should, so your body produces extra insulin to compensate. This extra insulin makes your ovaries produce even more androgens — so the two problems feed each other. It also raises your long-term risk for type 2 diabetes.
Insulin resistance is present in about 8 out of 10 people with PMOS — including many lean people. It is not caused by lack of willpower or poor lifestyle choices.
- Begin introducing PMOS alongside PCOS in patient conversations and documentation
- Use the transition period to update patient education materials
- Be prepared to explain the name change — many patients will encounter it from media before their clinician does
- Diagnostic criteria are unchanged; clinical management is unchanged
- Cardiovascular risk assessment and metabolic surveillance remain critical at diagnosis
- Watch for ICD-10/11 code transition guidance from your health system
The name change is official as of May 2026. But it will take up to 3 years for everything to catch up — medical records, drug labels, insurance codes, and textbooks all need updating. During this time, doctors may still use "PCOS" — both names are correct for now.
You can simply say: "I've been diagnosed with PCOS, which is now also called PMOS." Your medical history, diagnosis, and treatment remain the same. Nothing about your care changes because of the name.
Full consensus process, survey data (n=14,360), workshop methodology, and implementation strategy. Basis for name change content throughout this tool.
International diagnostic criteria and management framework; basis for Diagnosis tab content.
Source for "1 in 8 women" global prevalence figure.
CVD odds ratios (composite CVD OR 1.68; MI OR 2.50; stroke OR 1.71) cited in Clinical Features tab.
Adolescent-specific diagnostic criteria referenced in Diagnosis tab.
Comprehensive pathophysiology review; basis for Pathophysiology tab content.
AMH as diagnostic criterion; referenced in Diagnosis tab.
Insulin resistance prevalence data (85% overall, 75% lean) cited in Pathophysiology tab.
Confirms pathological ovarian cysts are not increased in PMOS; basis for the "polycystic misnomer" discussion.
Source for ~70% undiagnosed statistic cited in hero section.
Prior longitudinal survey showing 84% support for global consensus renaming process.
Polygenic architecture of PMOS; referenced in Pathophysiology tab.